Objective COVID-19 features include disseminated intravascular coagulation and thrombotic
microangiopathy indicating a hypercoagulable state. We aimed to investigate …

Abstract Background Coronavirus disease 19 (COVID‐19)–associated coagulopathy is a
hallmark of disease severity and poor prognosis. The key manifestations of this …

Abstract The coronavirus disease 2019 (COVID-19) is the largest public health emergency
in recent times. A significant number of patients develop a severe form of COVID-19 …

Background High incidence of thrombosis in COVID‐19 patients indicates a
hypercoagulable state. Hence, exploring the involvement of antiphospholipid antibodies …

High prevalence of both criteria and extra-criteria antiphospholipid antibodies (aPL) has
been reported in COVID-19 patients. However, the differences in aPL prevalence decreased …

Abstract Purpose of the Review Elevated levels of anti-phospholipid (aPL) antibodies are
the most important criterion in the diagnosis of anti-phospholipid syndrome (APS) and are …

Rapidly after the first description of the new coronavirus disease (COVID-19)[1], thrombotic
events were increasingly reported as a common complication [2–7]. Autopsy series further …

Coronavirus disease 2019 (COVID-19) is associated with a high rate of thrombosis.
Prolonged activated partial thromboplastin times (aPTT) and antiphospholipid antibodies …

Objective Coagulopathy is one of the characteristics observed in critically ill patients with
coronavirus disease 2019 (COVID‐19). Antiphospholipid antibodies (aPLs) contribute to …

Background Many studies reported high prevalence of antiphospholipid antibodies (aPL) in
patients with COVID-19 raising questions about its true prevalence and its clinical impact on …